Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Yearly Archives: 2012

Aegis Awarded Patent for Absorption-Enhancing Self-Assembling Thixotropic Aqueous Hydrogels

SAN DIEGO, CA December 12, 2012/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,329,220 providing proprietary compositions for absorption-enhancing self-assembling aqueous hydrogels useful for extended release, transdermal, or transmucosal absorption enhancement for peptide and small molecule drug delivery applications. The Aegis Hydrogels™ serve simultaneously as both delivery vehicle and […]

Aegis Awarded Patent for Fast Acting Intravail®-based Triptan Nasal Spray Formulations for Treating Migraine Headaches

SAN DIEGO, CA September 24, 2012/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,268,791 providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan.  The rapidly acting formulations utilize Aegis’ patented Intravail® […]

Aegis Awarded Patent for Monoclonal Antibody Formulations that Avoid Oxidative Damage Due to Polysorbate Surfactants

SAN DIEGO, CA July 24, 2012/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,226,949 providing broad protection for stabilized formulations of monoclonal antibodies.  The Aegis ProTek® excipients provide reduced immunogenicity while avoiding the oxidative damage caused by contaminating peroxides and reactive aldehydes intrinsic to the polysorbates such as Tween®-80, […]

Aegis Therapeutics Awarded Patent for Octreotide Formulations Suitable for Oral and Metered Nasal Spray Delivery

SAN DIEGO, CA  May 21, 2012/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,133,863 providing broad protection for pharmaceutical composition of octreotide. The highly stable octreotide formulations incorporate Aegis’ Intravail®/ProTek® excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection.  Intravail® and ProTek® excipients […]

Second Parathyroid Hormone (PTH) Peptide Drug Patent Awarded to Aegis Therapeutics for Compositions Suitable for Metered Nasal Spray, Oral, and Injectable Delivery

SAN DIEGO, CA  May 16, 2012/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded a second patent, U.S. Patent, No. 8,173,594, providing PTH and PTH analog compositions having increased stability and reduced aggregation and aggregation-associated immunogenicity.  The stabilized formulations of parathyroid hormone (PTH) and PTH peptide analogs incorporate Aegis’ Intravail®/ProTek® excipients suitable for […]

Aegis Awarded Patent for Interferon Alpha, Beta, and Gamma Formulations that Eliminate Aggregation and Associated Immunogenicity and are Suitable for Non-Invasive or Injectable Delivery

SAN DIEGO, CA  January 4, 2012/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,084,022 providing broad protection for stabilized formulations of alpha, beta, and gamma interferon suitable for non-invasive metered nasal spray delivery or traditional injection. Examples of approved interferon drugs include Betaferon®/Betaseron®/ (Bayer), Avonex®/ (Biogen Idec), Rebif®/ (EMD […]